Literature DB >> 15614618

Expression of prohibitin 3' untranslated region suppressor RNA alters morphology and inhibits motility of breast cancer cells.

Sharmila Manjeshwar1, Megan R Lerner, Xiao-Ping Zang, Dannielle E Branam, J Thomas Pento, Mary M Lane, Stan A Lightfoot, Daniel J Brackett, Eldon R Jupe.   

Abstract

The prohibitin 3' untranslated region (3'UTR) belongs to a novel class of non-coding regulatory RNAs. It arrests cell cycle progression by blocking G1-S transition in breast and other cancers. Our previous studies comparing MCF7 derived clones constitutively expressing a common allelic form of prohibitin RNA (UTR/C) to various controls demonstrated that it functions as a tumor suppressor. Here, we further characterized the morphology and motility of these transgenic breast cancer cells when grown in cell culture and on nude mice. In contrast to empty vector (EV) cells, UTR/C cells were observed to grow in an organized manner with more cell-cell contact and differentiate into structures with a duct-like appearance. Computer assisted cytometry to evaluate differences in nuclear morphology was performed on UTR/C and EV tissues from nude mice. Receiver operator curve areas generated using a logistic regression model were 0.8, indicating the ability to quantitatively distinguish UTR/C from EV tissues. Keratinocyte growth factor-induced motility experiments showed that migration of UTR/C cells was significantly reduced (80-90%) compared to EV cells. Together, these data indicate that this novel 3'UTR influences not only the tumorigenic phenotype but also may play a role in differentiation and migration of breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15614618     DOI: 10.1007/s10735-004-2185-7

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  33 in total

1.  Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression.

Authors:  L Beviglia; K Matsumoto; C S Lin; B L Ziober; R H Kramer
Journal:  Int J Cancer       Date:  1997-06-20       Impact factor: 7.396

2.  Minipodia, novel structures for extension of the lamella: a high-spatial-resolution video microscopic study.

Authors:  T P Cheng
Journal:  Exp Cell Res       Date:  1992-11       Impact factor: 3.905

3.  Transdifferentiation of chicken embryonic cells into muscle cells by the 3' untranslated region of muscle tropomyosin.

Authors:  T J L'Ecuyer; P C Tompach; E Morris; A B Fulton
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

4.  DNA ploidy and markovian analysis of neoplastic progression in experimental pancreatic cancer.

Authors:  Russell G Postier; Megan R Lerner; Stan A Lightfoot; Rick Vannarath; Mary M Lane; Jay S Hanas; Daniel J Brackett
Journal:  J Histochem Cytochem       Date:  2003-03       Impact factor: 2.479

5.  Prohibitin in breast cancer cell lines: loss of antiproliferative activity is linked to 3' untranslated region mutations.

Authors:  E R Jupe; X T Liu; J L Kiehlbauch; J K McClung; R T Dell'Orco
Journal:  Cell Growth Differ       Date:  1996-07

6.  Suppression of malignancy by the 3' untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs.

Authors:  H Fan; C Villegas; A Huang; J A Wright
Journal:  Cancer Res       Date:  1996-10-01       Impact factor: 12.701

7.  Keratinocyte growth factor is a growth factor for mammary epithelium in vivo. The mammary epithelium of lactating rats is resistant to the proliferative action of keratinocyte growth factor.

Authors:  T R Ulich; E S Yi; R Cardiff; S Yin; N Bikhazi; R Biltz; C F Morris; G F Pierce
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

8.  p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells.

Authors:  Mi-Sung Kim; Eun-Jung Lee; Hyeong-Reh Choi Kim; Aree Moon
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

9.  Tumor suppression by RNA from the 3' untranslated region of alpha-tropomyosin.

Authors:  F Rastinejad; M J Conboy; T A Rando; H M Blau
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

10.  Specific and non-specific KGF inhibition of KGF-induced breast cancer cell motility.

Authors:  Xiao-Ping Zang; Thao-Nguyen Nguyen; J Thomas Pento
Journal:  Anticancer Res       Date:  2002 Sep-Oct       Impact factor: 2.480

View more
  8 in total

Review 1.  The role and therapeutic potential of prohibitin in disease.

Authors:  Arianne L Theiss; Shanthi V Sitaraman
Journal:  Biochim Biophys Acta       Date:  2011-02-04

2.  Gonadotropin-releasing hormone-regulated prohibitin mediates apoptosis of the gonadotrope cells.

Authors:  Dana Savulescu; Jiajun Feng; Yueh Shyang Ping; Oliver Mai; Ulrich Boehm; Bin He; Bert W O'Malley; Philippa Melamed
Journal:  Mol Endocrinol       Date:  2013-10-01

3.  3' untranslated region 1630 C>T polymorphism of prohibitin increases risk of breast cancer.

Authors:  Lin Tang; Yunzhao Zhao; Weiwei Nie; Zexing Wang; Xiaoxiang Guan
Journal:  Onco Targets Ther       Date:  2013-03-09       Impact factor: 4.147

4.  Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.

Authors:  A Jakubowska; D Rozkrut; A Antoniou; U Hamann; R J Scott; L McGuffog; S Healy; O M Sinilnikova; G Rennert; F Lejbkowicz; A Flugelman; I L Andrulis; G Glendon; H Ozcelik; M Thomassen; M Paligo; P Aretini; J Kantala; B Aroer; A von Wachenfeldt; A Liljegren; N Loman; K Herbst; U Kristoffersson; R Rosenquist; P Karlsson; M Stenmark-Askmalm; B Melin; K L Nathanson; S M Domchek; T Byrski; T Huzarski; J Gronwald; J Menkiszak; C Cybulski; P Serrano; A Osorio; T R Cajal; M Tsitlaidou; J Benítez; M Gilbert; M Rookus; C M Aalfs; I Kluijt; J L Boessenkool-Pape; H E J Meijers-Heijboer; J C Oosterwijk; C J van Asperen; M J Blok; M R Nelen; A M W van den Ouweland; C Seynaeve; R B van der Luijt; P Devilee; D F Easton; S Peock; D Frost; R Platte; S D Ellis; E Fineberg; D G Evans; F Lalloo; R Eeles; C Jacobs; J Adlard; R Davidson; D Eccles; T Cole; J Cook; A Godwin; B Bove; D Stoppa-Lyonnet; V Caux-Moncoutier; M Belotti; C Tirapo; S Mazoyer; L Barjhoux; N Boutry-Kryza; P Pujol; I Coupier; J-P Peyrat; P Vennin; D Muller; J-P Fricker; L Venat-Bouvet; O Th Johannsson; C Isaacs; R Schmutzler; B Wappenschmidt; A Meindl; N Arnold; R Varon-Mateeva; D Niederacher; C Sutter; H Deissler; S Preisler-Adams; J Simard; P Soucy; F Durocher; G Chenevix-Trench; J Beesley; X Chen; T Rebbeck; F Couch; X Wang; N Lindor; Z Fredericksen; V S Pankratz; P Peterlongo; B Bonanni; S Fortuzzi; B Peissel; C Szabo; P L Mai; J T Loud; J Lubinski
Journal:  Br J Cancer       Date:  2012-05-15       Impact factor: 7.640

5.  Transcriptome analysis of a cnidarian-dinoflagellate mutualism reveals complex modulation of host gene expression.

Authors:  Mauricio Rodriguez-Lanetty; Wendy S Phillips; Virginia M Weis
Journal:  BMC Genomics       Date:  2006-02-10       Impact factor: 3.969

6.  Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism.

Authors:  Anna Jakubowska; Jacek Gronwald; Janusz Menkiszak; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Axel Benner; Jan Lubiński; Rodney J Scott; Ute Hamann
Journal:  BMC Cancer       Date:  2008-04-08       Impact factor: 4.430

7.  Prohibitin expression deregulation in gastric cancer is associated with the 3' untranslated region 1630 C>T polymorphism and copy number variation.

Authors:  Mariana Ferreira Leal; Priscila Daniele Ramos Cirilo; Tatiane Katsue Furuya Mazzotti; Danielle Queiroz Calcagno; Fernanda Wisnieski; Samia Demachki; Margarita Cortes Martinez; Paulo Pimentel Assumpção; Roger Chammas; Rommel Rodríguez Burbano; Marília Cardoso Smith
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

8.  Antiosteoporotic Effects of Huangqi Sanxian Decoction in Cultured Rat Osteoblasts by Proteomic Characterization of the Target and Mechanism.

Authors:  Chong-Chong Guo; Li-Hua Zheng; Jian-Ying Fu; Jian-Hong Zhu; Yan-Xing Zhou; Tao Zeng; Zhi-Kun Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-18       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.